Organoid-derived C-Kit+/SSEA4− human retinal progenitor cells promote a protective retinal microenvironment during transplantation in rodents

Stem cell therapy may replace lost photoreceptors and preserve residual photoreceptors during retinal degeneration (RD). Unfortunately, the degenerative microenvironment compromises the fate of grafted cells, demanding supplementary strategies for microenvironment regulation. Donor cells with both proper regeneration capability and intrinsic ability to improve microenvironment are highly desired. Here, we use cell surface markers (C-Kit+/SSEA4−) to effectively eliminate tumorigenic embryonic cells and enrich retinal progenitor cells (RPCs) from human embryonic stem cell (hESC)-derived retinal organoids, which, following subretinal transplantation into RD models of rats and mice, significantly improve vision and preserve the retinal structure. We characterize the pattern of integration and materials transfer following transplantation, which likely contribute to the rescued photoreceptors. Moreover, C-Kit+/SSEA4− cells suppress microglial activation, gliosis and the production of inflammatory mediators, thereby providing a healthier host microenvironment for the grafted cells and delaying RD. Therefore, C-Kit+/SSEA4− cells from hESC-derived retinal organoids are a promising therapeutic cell source.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection Leica Application Suite X was used for confocal laser scanning microscopy. Flow cytometry data were collected by FACS DIVA or FACS CellQuest Pro software Data analysis ImageJ V1.51 was used to analyse confocal images and Western blots. Product and Service Solutions software V22.0 (SPSS) was used for statistical analyses. FlowJo V10 was used for flow cytometry dada.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The raw data that support the findings of this study are available from the corresponding author upon reasonable request. The data of transcriptome analysis in this study has been deposited in the NCBI sequence read archive database under accession code PRJNA506329.

nature research | reporting summary
October 2018 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
It is generally considered that a sample size containing at least 3 biological replicates can provide adequate statistical power in biochemical analysis. We have described the exact sample size for each experiment in our manuscript.
Data exclusions No data captured was excluded from the subsequent analyses

Replication
The exact number of replication for all experiments was described in figure legends and our attempts at replication were successful.
Randomization Samples and animals were allocated randomly.

Blinding
Microglia analysis, outer nuclear thickness analysis and and optokinetic head tracking test were performed in a blind method.

Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.

Study description
Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Data collection
Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Timing
Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

Data exclusions
If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation
State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization
If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sampling strategy
Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data collection
Describe the data collection procedure, including who recorded the data and how.

Access and import/export
Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).

Disturbance
Describe any disturbance caused by the study and how it was minimized.

Authentication
The human embryonic stem cell line (H9) and immortalized human microglia-SV40 cell line have been authenticated through short tandem repeat technology.

Mycoplasma contamination
All the cell lines had been tested and confirmed negative for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)
None of the cell lines used in this paper are listed in the database of commonly misidentified cell lines maintained by ICLAC.

Palaeontology Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals
Royal College of Surgeons (RCS) rats and rd1 mice, regardless of sex, were provided by the Experimental Animal Center of Third Military Medical University (Army Medical University).

Wild animals
The study did not involve wild animals.

Field-collected samples
The study did not involve samples collected from the field.

Ethics oversight
All animal work has been approved by the Institutional Review Board of the Third Military Medical University (Army Medical University). This study was approved by the ethics committee of Southwest Hospital, Third Military Medical University (Army Medical University).
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants

Ethics oversight
Identify the organization(s) that approved the study protocol.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

nature research | reporting summary
October 2018 Clinical data Policy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol
Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission
Provide a list of all files available in the database submission.
Genome browser session (e.g. UCSC) Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology Replicates
Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.

Antibodies
Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

Peak calling parameters
Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

Data quality
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

Software
Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry
Plots Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Instrument
All flow cytometry was performed on BD FACS Aria II or BD FACS Calibur flow cytometer.

Software
The data were collected by FACS DIVA or FACS CellQuest Pro software and analyzed with FlowJo software. 6 nature research | reporting summary

October 2018
Cell population abundance Freshly sorted C-Kit+/SSEA4-cells were resorted to > 98% purity using a BD FACSAria II.

Gating strategy
For live cell sorting, cells were gated first on live cell populations according to forward scatter (FSC) and side scatter (SSC) and single cells were identified according to SSC-W/SSC-H. The viability dye 7-AAD dye was used to further exclude dead cells. For cells after fixation and permeabilization, cells were gated first according to forward scatter (FSC) and side scatter (SSC) and single cells were identified according to SSC-W/SSC-H. The voltage of a specific fluorescence between positive and negative staining cell populations was adjusted to be appropriate according to isotype staining before flow cytometry experiments. Then the identification of specific cell subsets was detailed in the figure legends.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging
Experimental design